Home > Mobocertinib (TAK-788)

molecules of the month

<< Back to February

Mobocertinib (TAK-788)

Recent Publication

EGFR exon 20 mutant inhibitor, oral once-daily

Breakthrough Therapy for ex20+ NSCLC (Ph. I)

from cellular screening + SBDD

Cancer Discovery, Feb. 25, 2021

ARIAD/Takeda, Cambridge, MA

4. The ARIAD/Takeda EGFR exon 20 insertion mutant (EGFRex20ins) inhibitor TAK-788 is a Breakthrough Therapy for patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbor EGFR exon…

this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.

LEARN MORE

Mobocertinib (TAK-788)

this content is exclusive to Premium members

this content is exclusive to
Premium members